Sex: M
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Back pain, Body temperature increased, Cough
Clinical narrative: he got really sick on Sunday; coughing; sneezing; nose started running; sore throat; complaining about back pain on lung side in patient's right upper quadrant; Patient had an elevated temperature but no fever; loosing smell and taste; loosing smell and taste; This is a spontaneous report received from a contactable reporter(s) (Nurse) from medical information team.  A 65-year-old male patient received BNT162b2 (BNT162B2), as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "heart condition (waiting for a hear surgery)" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete but unknown manufacturer), for Covid-19 Immunization. The following information was reported: ILLNESS (medically significant), outcome "unknown", described as "he got really sick on Sunday"; COUGH (non-serious), outcome "unknown", described as "coughing"; SNEEZING (non-serious), outcome "unknown"; RHINORRHOEA (non-serious), outcome "unknown", described as "nose started running"; OROPHARYNGEAL PAIN (non-serious), outcome "unknown", described as "sore throat"; BACK PAIN (non-serious), outcome "unknown", described as "complaining about back pain on lung side in patient's right upper quadrant"; BODY TEMPERATURE INCREASED (non-serious), outcome "unknown", described as "Patient had an elevated temperature but no fever"; ANOSMIA (non-serious), AGEUSIA (non-serious), outcome "unknown" and all described as "loosing smell and taste". The patient underwent the following laboratory tests and procedures: Body temperature increased: elevated. Clinical significance: Caller was calling about the Pfizer COVID-19 vaccine. Caller's husband, the patient, got the booster about 2.5 to 3 weeks ago and got really sick on Sunday. Patient went to urgent care on Tuesday and was diagnosed with Covid-19 on Tuesday. On Sunday the patient started coughing, sneezing, nose started running, sore throat, and complaining about back pain on lung side in patient's right upper quadrant. Patient had an elevated temperature but no fever. Patient mentioned last night that he was loosing smell and taste. The husband (patient) with heart condition (waiting for a hear surgery). Caller would like to know if its possible to get the virus (Infection) from the Booster dose / vaccine?  She had heard that most patients get covid from the booster shot. Caller stated that Obviously the third vaccine (booster dose) did not work in his body to build up antibodies and that's why he got full blown covid, isn't it? She has heard from many patients that the booster shot this mRNA is not working because patients get infection after the booster shot. Confirms the booster dose was the patient's 3rd dose, 1st booster dose. Description of Product Complaint: Description of complaint: Got the 3rd dose, 1st booster dose, about 2.5 to 3 weeks ago and got really sick on Sunday. Diagnosed with Covid-19 on Tuesday. Declined to complete report. NDC number, lot number, expiration date: Not provided. COVID-19 vaccine was a Pfizer product. PQC Present: No AE Present: Yes  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.  Follow-up (19May2022): This is a follow-up report received from the contactable Nurse. This Nurse reported for a 65-year-old male patient that included updated information: Event (coughing, sneezing, nose started running, sore throat, complaining about back pain on lung side in patient's right upper quadrant, Patient had an elevated temperature but no fever and loosing smell and taste added) and additional information.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.  Follow-up (20May2022): This is a follow-up report received in response to the mail trail sent regarding the confirmation below mentioned query. The response included reporter information and additional information.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of the reported events cannot be totally excluded.   The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.